FGFR2 and cholangiocarcinoma: Previous results indicated a maximum disease control rate (DCR) of 80% and progression-free survival (PFS) of approximately 6 months [14,20,21]; therefore, FGFR inhibitors are promising drugs for targeted therapies for CCA with FGFR2 fusions.